Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O(6)-Methylguanine-DNA Methyltransferase Biomarker Analyses

UZH-Logo

Cloughesy, Timothy; Finocchiaro, Gaetano; Belda-Iniesta, Cristóbal; Recht, Lawrence; Brandes, Alba A; Pineda, Estela; Mikkelsen, Tom; Chinot, Olivier L; Balana, Carmen; Macdonald, David R; Westphal, Manfred; Hopkins, Kirsten; Weller, Michael; Bais, Carlos; Sandmann, Thomas; Bruey, Jean-Marie; Koeppen, Hartmut; Liu, Bo; Verret, Wendy; Phan, See-Chun; Shames, David S (2017). Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O(6)-Methylguanine-DNA Methyltransferase Biomarker Analyses. Journal of Clinical Oncology, 35(3):343-351.

Dimensions.ai Metrics

173 downloads since deposited on 27 Oct 2017
81 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:	Journal Article, refereed, original work
Communities & Collections:	04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:	610 Medicine & health
Scopus Subject Areas:	Health Sciences > Oncology Life Sciences > Cancer Research
Language:	English
Date:	20 January 2017
Deposited On:	27 Oct 2017 07:09
Last Modified:	26 Jan 2022 13:55
Publisher:	American Society of Clinical Oncology
ISSN:	0732-183X
OA Status:	Green
Free access at:	Publisher DOI. An embargo period may apply.
Publisher DOI:	https://doi.org/10.1200/JCO.2015.64.7685
PubMed ID:	27918718